Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
----------
AIM - WINNERS
----------
Parkmead Group PLC, up 17% at 49.80 pence, 12-month range 34.40p-64.40p. The Netherlands and UK-focused gas explorer says its assets "continue to perform well". It has benefitted from surging gas prices in Europe. As a result, it expects annual gas revenue, from its Dutch assets, to exceed EUR14.5 million for the year ended June - which is ahead of internal expectations.
----------
Surface Transforms PLC, up 7.0% at 46.53 pence, 12-month range 36.00p-70.50p. The Liverpool-based manufacturer of carbon fibre reinforced ceramic materials is "confident" it can achieve profit in 2022. Revenue in the first half of the year surges to GBP2.9 million from GBP1.2 million a year earlier, thanks in part to deliveries on the Aston Martin Lagonda Holdings PLC Valkyrie sports car project.
----------
AIM - LOSERS
----------
Attraqt Group PLC, down 12% at 22.00p, 12-month range 21.91p-45.00p. The London-based provider of online search, merchandising and personalisation solutions for e-commerce expects a weakening economic outlook to "delay some customer decisions" and lengthen enterprise sales lead times. However, the company adds that revenue for the first half of 2022 rises 8% year-on-year at constant currency to GBP12.1 million.
----------
Hutchmed (China) Ltd, down 4.6% at 240.50p, 12-month range 1.38p-247.00p. The stock falls as tens of millions more people are put under lockdown in China on Wednesday as businesses in a major tourist city are forced to shut their doors and fresh clusters sparked fears of a return to blanket restrictions. Health authorities have reported over 300 infections Wednesday, with clusters found in the historic northern city of Xi'an – home to the Terracotta Army – as well as the country's biggest city Shanghai. Also on Wednesday, Hutchmed says it has dosed a first patient for its phase I trial for IMG-007. The Hong Kong-based biopharmaceutical firm said the trial will test the investigational OX40 antagonistic monoclonal antibody for the treatment of moderate to severe atopic dermatitis.
----------
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
